Cardiology and Therapy (Nov 2023)

Cardiovascular Compatibility of Proton Pump Inhibitors: Practice Recommendations

  • Jamshed Dalal,
  • Anjan Lal Dutta,
  • Jagdish Hiremath,
  • Shamanna Seshadri Iyengar,
  • Jagadish Chander Mohan,
  • Abraham Ooman,
  • Bhabadev Goswami,
  • Kotacherry Thrivikrama Shenoy

DOI
https://doi.org/10.1007/s40119-023-00338-1
Journal volume & issue
Vol. 12, no. 4
pp. 557 – 570

Abstract

Read online

Abstract This manuscript aims to critically evaluate the current evidence regarding adverse cardiovascular effects associated with proton pump inhibitors (PPIs) in patients with coronary artery disease (CAD). It also provides guidance for the selection of the most appropriate PPI within the context of cardiovascular polypharmacy and emphasizes the importance of establishing consensus among clinicians on the need to prescribe PPIs with limited cytochrome P450 (CYP450) enzyme inhibition to reduce the risk of drug interactions. PPIs are among the most widely used drugs for the treatment of gastroesophageal reflux disease (GERD) and the prevention of gastrointestinal (GI) bleeding. The manuscript reports the proceedings from the first practice recommendations meeting on the cardiovascular compatibility of PPIs in an Indian setting. A panel of eight Indian experts in cardiology and gastroenterology reviewed 14 consensus statements. Available literature was searched and summarized, and after multiple rounds of review, consensus was achieved for these statements. Based on the available evidence, the consensus panel highlights that a PPI with minimal drug–drug interaction (DDI) is recommended, especially in patients requiring clopidogrel or polypharmacy. Rabeprazole appears to be a good option in cases where co-prescription is indicated, owing to its optimal acid suppression and minimal drug interaction profile.

Keywords